Toll-like receptor-induced reactivity and strongly potentiated IL-8 production in granulocytes mobilized for transfusion purposes

Blood

Volumn 115, Issue 22, 2010, Pages 4588-4596

  Drewniak, Agata ^a,b   Tool, Anton T J ^a   Geissler, Judy ^a   Van Bruggen, Robin ^a   Van Den Berg, Timo K ^a   Kuijpers, Taco W ^a,b  

^a SANQUIN RESEARCH   (Netherlands)

^b UNIVERSITY OF AMSTERDAM   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

DEXAMETHASONE; GRANULOCYTE COLONY STIMULATING FACTOR; INTERLEUKIN 8; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; TOLL LIKE RECEPTOR; TOLL LIKE RECEPTOR 2; TOLL LIKE RECEPTOR 4; TOLL LIKE RECEPTOR 5; TOLL LIKE RECEPTOR 8; CHEMOKINE; IL8 PROTEIN, HUMAN; MESSENGER RNA; PRIMER DNA; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR;

ANTIMICROBIAL THERAPY; ARTICLE; CELL ADHESION; CONTROLLED STUDY; CYTOKINE PRODUCTION; ENZYME ACTIVITY; GENE EXPRESSION; GRANULOCYTE; HUMAN; HUMAN CELL; IMMUNOPOTENTIATION; IN VIVO STUDY; LEUKOCYTE TRANSFUSION; NEUTROPENIA; NEUTROPHIL; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; TRANSCRIPTION REGULATION; BIOSYNTHESIS; BLOOD; DRUG EFFECT; GENETICS; IMMUNOLOGY; IN VITRO STUDY; LEUKAPHERESIS; PHYSIOLOGY; STEM CELL MOBILIZATION; TRANSPLANTATION;

BASE SEQUENCE; CELL ADHESION; CHEMOKINES; DEXAMETHASONE; DNA PRIMERS; GRANULOCYTE COLONY STIMULATING FACTOR, RECOMBINANT; GRANULOCYTES; HEMATOPOIETIC STEM CELL MOBILIZATION; HUMANS; INTERLEUKIN-8; LEUKAPHERESIS; LEUKOCYTE TRANSFUSION; RNA, MESSENGER; TOLL-LIKE RECEPTORS;

EID: 77953936792     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2009-11-253245     Document Type: Article

References (47)

1. Peters C. Granulocyte transfusions in neutropenic patients: beneficial effects proven? Vox Sang. 2009;96(4):275-283.
2. Drewniak A, Kuijpers TW. Granulocyte transfusions: randomization after all? Haematologica. 2009;94(12):1644-1648.
3. Price TH, Bowden RA, Boeckh M, et al. Phase I/II trial of neutrophil transfusions from donors stimulated with G-CSF and dexamethasone for treatment of patients with infections in hematopoietic stem cell transplantation. Blood. 2000;95(11):3302-3309.
4. Price TH. The current prospects for neutrophil transfusions for the treatment of granulocytopenic infected patients. Transfus Med Rev. 2000;14(1):2-11.
5. Dale DC, Liles WC, Llewellyn C, Rodger E, Price TH. Neutrophil transfusions: kinetics and functions of neutrophils mobilized with granulocyte-colony-stimulating factor and dexamethasone. Transfusion. 1998;38(8):713-721.
6. Drewniak A, Boelens JJ, Vrielink H, et al. Granulocyte concentrates: prolonged functional capacity during storage in the presence of phenotypic changes. Haematologica. 2008;63(7):1059-1067.
7. Drewniak A, van Raam BJ, Geissler J, et al. Changes in gene expression of granulocytes during in vivo G-CSF/dexamethasone mobilization for transfusion purposes. Blood. 2009;113(23):5979-5998.
8. Moynagh PN. TLR signalling and activation of IRFs: revisiting old friends from the NF-kappaB pathway. Trends Immunol. 2005;26(9):469-476.
9. Kurt-Jones EA, Mandell L, Whitney C, et al. Role of toll-like receptor 2 (TLR2) in neutrophil activation: GM-CSF enhances TLR2 expression and TLR2-mediated interleukin 8 responses in neutrophils. Blood. 2002;100(5):1860-1868.
10. Hayashi F, Means TK, Luster AD. Toll-like receptors stimulate human neutrophil function. Blood. 2003;102(7):2660-2669.
11. Francois S, El Benna J, Dang PM, et al. Inhibition of neutrophil apoptosis by TLR agonists in whole blood: involvement of the phosphoinositide 3-kinase/Akt and NF-kappaB signaling pathways, leading to increased levels of Mcl-1, A1, and phosphorylated Bad. J Immunol. 2005;174(6):3633-3642.
12. Cassatella MA. Neutrophil-derived proteins: selling cytokines by the pound. Adv Immunol. 1999;73:369-509.
13. Larsen CG, Anderson AO, Appella E, Oppenheim JJ, Matsushima K. The neutrophil-activating protein (NAP-1) is also chemotactic for T lymphocytes. Science. 1989;243(4879):1464-1466.
14. Baggiolini M. Novel aspects of inflammation: interleukin-8 and related chemotactic cytokines. Clin Investig. 1993;71(10):812-814.
15. Gerszten RE, Garcia-Zepeda EA, Lim YC, et al. MCP-1 and IL-8 trigger firm adhesion of monocytes to vascular endothelium under flow conditions. Nature. 1999;398(6729):718-723.
16. Rollins BJ. Chemokines. Blood. 1997;90(3):909-928.
17. Roos D, de Boer M. Purification and cryopreservation of phagocytes from human blood. Methods Enzymol. 1986;132:225-243.
18. Kuijpers TW, Tool AT, van der Schoot CE, et al. Membrane surface antigen expression on neutrophils: a reappraisal of the use of surface markers for neutrophil activation. Blood. 1991;78(4):1105-1111.
19. van Mirre E, Breunis WB, Geissler J, et al. Neutrophil responsiveness to IgG, as determined by fixed ratios of mRNA levels for activating and inhibitory FcgammaRII (CD32), is stable over time and unaffected by cytokines. Blood. 2006;108(2):584-590.
20. National Center for Biotechnology Information. BLAST: Basic Local Alignment Search Tool. http://www.ncbi.nlm.nih.gov/BLAST/. Accessed June 2009.
21. Nagase H, Okugawa S, Ota Y, et al. Expression and function of Toll-like receptors in eosinophils: activation by Toll-like receptor 7 ligand. J Immunol. 2003;171(8):3977-3982.
22. Guthrie LA, McPhail LC, Henson PM, Johnston RB Jr. Priming of neutrophils for enhanced release of oxygen metabolites by bacterial lipopolysaccharide. Evidence for increased activity of the superoxide-producing enzyme. J Exp Med. 1984;160(6):1656-1671.
23. Forehand JR, Pabst MJ, Phillips WA, Johnston RB Jr. Lipopolysaccharide priming of human neutrophils for an enhanced respiratory burst. Role of intracellular free calcium. J Clin Invest. 1989;83(1):74-83.
24. Condliffe AM, Kitchen E, Chilvers ER. Neutrophil priming: pathophysiological consequences and underlying mechanisms. Clin Sci (Lond). 1998;94(5):461-471.
25. Sabroe I, Prince LR, Jones EC, et al. Selective roles for Toll-like receptor (TLR)2 and TLR4 in the regulation of neutrophil activation and life span. J Immunol. 2003;170(10):5268-5275.
26. Scapini P, Lapinet-Vera JA, Gasperini S, et al. The neutrophil as a cellular source of chemokines. Immunol Rev. 2000;177:195-203.
27. Yoshimura T, Takahashi M. IFN-gamma-mediated survival enables human neutrophils to produce MCP-1/CCL2 in response to activation by TLR ligands. J Immunol. 2007;179(3):1942-1949.
28. Smedman C, Gardlund B, Nihlmark K, et al. ELISpot analysis of LPS-stimulated leukocytes: human granulocytes selectively secrete IL-8, MIP-1beta and TNF-alpha. J Immunol Methods. 2009;346(1-2):1-8.
29. Wertheim WA, Kunkel SL, Standiford TJ, et al. Regulation of neutrophil-derived IL-8: the role of prostaglandin E2, dexamethasone, and IL-4. J Immunol. 1993;151(4):2166-2175.
30. Marie C, Fitting C, Cheval C, et al. Presence of high levels of leukocyte-associated interleukin-8 upon cell activation and in patients with sepsis syndrome. Infect Immun. 1997;65(3):865-871.
31. Pellme S, Morgelin M, Tapper H, et al. Localization of human neutrophil interleukin-8 (CXCL-8) to organelle(s) distinct from the classical granules and secretory vesicles. J Leukoc Biol. 2006;79(3):564-573.
32. Liles WC, Huang JE, Llewellyn C, et al. A comparative trial of granulocyte-colony-stimulating factor and dexamethasone, separately and in combination, for the mobilization of neutrophils in the peripheral blood of normal volunteers. Transfusion. 1997;37(2):182-187.
33. Liles WC, Huang JE, van Burik JA, Bowden RA, Dale DC. Granulocyte colony-stimulating factor administered in vivo augments neutrophil-mediated activity against opportunistic fungal pathogens. J Infect Dis. 1997;175(4):1012-1015.
34. Leavey PJ, Sellins KS, Thurman G, et al. In vivo treatment with granulocyte colony-stimulating factor results in divergent effects on neutrophil functions measured in vitro. Blood. 1998;92(11):4366-4374.
35. Rhen T, Cidlowski JA. Antiinflammatory action of glucocorticoids-new mechanisms for old drugs. N Engl J Med. 2005;353(16):1711-1723.
36. Altstaedt J, Kirchner H, Rink L. Cytokine production of neutrophils is limited to interleukin-8. Immunology. 1996;89(4):563-568.
37. Cassatella MA, Bazzoni F, Ceska M, et al. IL-8 production by human polymorphonuclear leukocytes. The chemoattractant formyl-methionyl-leucyl- phenylalanine induces the gene expression and release of IL-8 through a pertussis toxinsensitive pathway. J Immunol. 1992;148(10):3216-3220.
38. Strieter RM, Kasahara K, Allen RM, et al. Cytokine-induced neutrophil-derived interleukin-8. Am J Pathol. 1992;141(2):397-407.
39. Hoffmann E, Dittrich-Breiholz O, Holtmann H, Kracht M. Multiple control of interleukin-8 gene expression. J Leukoc Biol. 2002;72(5):847-855.
40. Tobler A, Meier R, Seitz M, et al. Glucocorticoids downregulate gene expression of GM-CSF, NAP-1/IL-8, and IL-6, but not of M-CSF in human fibroblasts. Blood. 1992;79(1):45-51.
41. Stellato C. Post-transcriptional and nongenomic effects of glucocorticoids. Proc Am Thorac Soc. 2004;1(3):255-263.
42. Caput D, Beutler B, Hartog K, et al. Identification of a common nucleotide sequence in the 3′-untranslated region of mRNA molecules specifying inflammatory mediators. Proc Natl Acad Sci U S A. 1986;83(6):1670-1674.
43. Shaw G, Kamen R. A conserved AU sequence from the 3′ untranslated region of GM-CSF mRNA mediates selective mRNA degradation. Cell. 1986;46(5):659-667.
44. Zhang T, Kruys V, Huez G, Gueydan C. AU-rich element-mediated translational control: complexity and multiple activities of trans-activating factors. Biochem Soc Trans. 30(Pt. 6):952-958, 2002.
45. Espel E. The role of the AU-rich elements of mRNAs in controlling translation. Semin Cell Dev Biol. 2005(1):16:59-67.
46. Winzen R, Gowrishankar G, Bollig F, et al. Distinct domains of AU-rich elements exert different functions in mRNA destabilization and stabilization by p38 mitogen-activated protein kinase or HuR. Mol Cell Biol. 2004;24(11):4835- 4847.
47. Mazumder B, Seshadri V, Fox PL. Translational control by the 3′-UTR: the ends specify the means. Trends Biochem Sci. 2003;28(2):91-98.